University of Salerno
🇮🇹Italy
Clinical Trials
16
Active:0
Completed:5
Trial Phases
3 Phases
Phase 3:1
Phase 4:2
Not Applicable:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Not Applicable
4 (57.1%)Phase 4
2 (28.6%)Phase 3
1 (14.3%)Effectiveness of a Cardiac Telerehabilitation Program in Chronic Heart Failure
Not yet recruiting
- Conditions
- Heart Failure
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- University of Salerno
- Target Recruit Count
- 205
- Registration Number
- NCT07023536
AI-Based Monitoring System for Chronic Heart Failure With Advanced Wearable and Mini-Invasive Devices
Not yet recruiting
- Conditions
- Chronic Heart FailureCardiovascular DiseasesHeart Failure With Reduced Ejection Fraction (HFrEF)Heart Failure With Preserved Ejection Fraction (HFPEF)Congestive Heart Failure Chronic
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- University of Salerno
- Target Recruit Count
- 205
- Registration Number
- NCT06909682
Efficacy and Safety of Transcranial dIrect Current stiMulation in Multiple System Atrophy-Cerebellar Variant
Not Applicable
Recruiting
- Conditions
- Multiple System Atrophy - Cerebellar Subtype (MSA-C)
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- University of Salerno
- Target Recruit Count
- 30
- Registration Number
- NCT06821256
- Locations
- 🇮🇹
Centro per le Malattie Neurodegenerative (CEMAND) Dipartimento di Medicina e chirurgia, Sezione Neuroscienze, Università di Salerno, Salerno, Sa, Italy
Transcatheter Aortic Valve Replacement in Severe Low Flow, Low Gradient Aortic Stenosis
Recruiting
- Conditions
- Low Flow, Low Gradient Aortic Stenosis
- First Posted Date
- 2024-09-10
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- University of Salerno
- Target Recruit Count
- 1500
- Registration Number
- NCT06589063
- Locations
- 🇮🇹
University of Salerno, Salerno, Italy
Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients
Phase 4
Not yet recruiting
- Conditions
- Lipid Metabolism DisordersStatin Adverse ReactionCardiovascular DiseasesDyslipidemias
- Interventions
- Drug: Lipid-lowering therapy combination with PCSK9 inhibitors, bempedoic acid and ezetimibeDrug: Lipid-lowering therapy combination with PCSK9 inhibitors and ezetimibe
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- University of Salerno
- Target Recruit Count
- 130
- Registration Number
- NCT06381947
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found